BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
58.54
-0.27 (-0.46%)
Jul 31, 2025, 12:56 PM - Market open

Company Description

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.

The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.

It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A.

The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy.

It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers.

The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical logo
CountryUnited States
Founded1996
IPO DateJul 23, 1999
IndustryBiotechnology
SectorHealthcare
Employees3,040
CEOAlexander Hardy

Contact Details

Address:
770 Lindaro Street
San Rafael, California 94901
United States
Phone415 506 6700
Websitebiomarin.com

Stock Details

Ticker SymbolBMRN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001048477
CUSIP Number09061G101
ISIN NumberUS09061G1013
Employer ID68-0397820
SIC Code2834

Key Executives

NamePosition
Alexander HardyPresident, Chief Executive Officer and Director
Brian R. Mueller C.P.A.Executive Vice President of Finance and Chief Financial Officer
George Eric Davis J.D.Executive Vice President, Chief Legal Officer, General Counsel and Secretary
Cristin HubbardExecutive Vice President and Chief Commercial Officer
Dr. Gregory Friberg M.D.Executive Vice President and Chief Research and Development Officer
Erin BurkhartGroup Vice President and Chief Accounting Officer
Dr. C. Greg Guyer Ph.D.Executive Vice President and Chief Technology Officer
Dr. Kevin Eggan Ph.D.Chief Scientific Officer and Senior Vice President of Research and Early Development
Amy WiremanExecutive Vice President and Chief People Officer
Dr. Ganesh Vedantham Ph.D.Senior Vice President of Technical Development

Latest SEC Filings

DateTypeTitle
May 22, 20258-KCurrent Report
May 20, 2025144Filing
May 16, 2025SC TO-CFiling
May 16, 20258-KCurrent Report
May 13, 2025SCHEDULE 13G/AFiling
May 2, 202510-QQuarterly Report
May 2, 2025144Filing
May 1, 20258-KCurrent Report
Apr 29, 2025SCHEDULE 13G/AFiling
Apr 8, 2025ARSFiling